the hemodynamic and clinical effects of parenteral and oral ci-930 , a new phosphodiesterase type iii inhibitor with combined vasodilator and inotropic properties , were studied in 12 patients with severe congestive heart failure refractory to therapy including captopril .
C0018802
congestive heart failure
C0006938
captopril